Presidio Property Trust, Inc. (SQFT) - 2024 Annual Report Summary
Business Context and Reporting Period
This summary covers the Form 10-K for Presidio Property Trust, Inc. (the "Company"), an internally-managed Real Estate Investment Trust (REIT), for the fiscal year ended December 31, 2024. The Company invests in a diversified portfolio of commercial real estate (office, industrial, retail) and model homes leased back to homebuilders. As of year-end, the portfolio consisted of 12 commercial properties and 78 model homes located primarily in Colorado, North Dakota, Texas, California, Maryland, Florida, and Arizona.
Key Financial Metrics
- Revenue: Total revenue was $18.9 million for 2024, an increase of 7.3% from $17.6 million in 2023. This growth was driven by new commercial leases and model home transaction fees.
- Net Income (Loss): The Company reported a net loss of $23.1 million for 2024, compared to net income of $13.2 million in 2023. The loss was primarily driven by a $17.9 million unrealized loss on the Company's investment in Conduit Pharmaceuticals (CDT) marketable securities.
- Net Operating Income (NOI): Total NOI was $12.7 million. Adjusted NOI for the Model Home segment (including gains on sales) was $7.3 million.
- Debt: Total gross indebtedness was approximately $102.8 million. The weighted-average interest rate on commercial mortgage notes was 5.24%, and 6.78% for model home notes.
- Liquidity: Cash, cash equivalents, and restricted cash totaled $8.0 million as of December 31, 2024.
- Dividends: The Company paid monthly dividends on Series D Preferred Stock totaling $2.34 per share. No dividends were declared or paid on Series A Common Stock in 2024.
Material Changes vs. Prior Period
- Investment Losses: The most significant change was the $17.9 million loss on the Conduit Pharmaceuticals investment, down from a $40.3 million gain on deconsolidation in 2023. The fair value of the investment dropped from $18.3 million in 2023 to $0.2 million in 2024.
- Impairments: The Company recorded $2.0 million in non-cash impairment charges in 2024 (down from $3.2 million in 2023). This included $1.4 million related to commercial properties (Dakota Center and 300 NP) and $0.4 million related to model homes.
- Acquisitions and Dispositions:
- Acquisitions: Acquired 19 model homes for $9.7 million (down from 40 homes for $21.9 million in 2023). No commercial properties were acquired in 2024.
- Dispositions: Sold 51 model homes for $24.8 million, recognizing a gain of $3.4 million. In 2023, 22 model homes were sold for $11.7 million.
- Operating Expenses: General and Administrative (G&A) expenses increased to $7.5 million (from $6.8 million) due to costs associated with an activist stockholder settlement and annual meeting.
Guidance, Outlook, and Risks
- Debt Maturities: The Company faces significant debt maturities in 2025, totaling approximately $38.8 million ($30.5 million for commercial properties and $8.3 million for model homes). Management is actively working to refinance or sell properties to settle these obligations.
- Property Sales: Two commercial properties (Union Town Center and Research Parkway) were sold in February 2025 for a combined $16.95 million, generating a $4.0 million gain. The Dakota Center property is listed for sale to settle a matured non-recourse loan.
- Stock Repurchases: The Board authorized a new repurchase program in December 2024 for up to $6.0 million of Series A Common Stock and $4.0 million of Series D Preferred Stock, expiring in December 2025.
- Nasdaq Compliance: The Company received an extension from Nasdaq until June 2, 2025, to regain compliance with the $1.00 minimum bid price requirement. Failure to comply could result in delisting.
- Risks: Key risks include the inability to refinance maturing debt, the volatility of the Conduit Pharmaceuticals investment, and the concentration of model homes in Texas (94% of the portfolio).
Investor Verification Checklist
- Debt Refinancing: Verify the status of refinancing efforts for the $30.5 million in commercial debt maturing in 2025, specifically for One Park Centre, Genesis Plaza, and Shea Center II.
- Conduit Investment: Monitor the fair value of the remaining Conduit Pharmaceuticals investment ($0.2 million) and the impact of the 1-for-100 reverse stock split on the Company's holdings.
- Nasdaq Listing: Track the Company's stock price to ensure it meets the $1.00 minimum bid price requirement by June 2, 2025, to avoid delisting.
- Dividend Policy: Confirm if the Board will resume dividends on Series A Common Stock, given the suspension in 2024 and the net loss position.
- Property Sales: Verify the final sale price and proceeds for the Dakota Center property, which is being sold to settle a matured loan.